INCELL Corporation

INCELL, a Texas limited liability corporation (LLC), was incorporated in 1993 in San Antonio. Mary Pat Moyer, Ph.D., Director of the Center for Human Cell Biotechnology at The University of Texas Health Science Center at San Antonio, founded INCELL as a spin-off of her unique, pioneering technologies for culturing human cells in vitro, combined with multidisciplinary expertise. INCELL's mission is to improve medical research, diagnosis, treatment, and disease prevention by providing specialty products and services for biomedicine and biotechnology applications with human and animal cells in vitro and animal and microbial systems in vivo. INCELL's specialty products, expert Consultant Scientists, client-customized contract research and testing protocols, high quality services, dependability and reasonable costs are assisting scientists and managers who prefer to outsource pre-clinical work, particularly studies that require the use of human cells and tissues.

INCELL's unique and broad-ranging capabilities combined with ongoing research efforts contribute to the development pipeline of future products and clinical applications. INCELL has the specific intent to help bring "translational" research to the clinic. The corporation thus provides contract testing services and performs basic scientific and clinical research in the areas of toxicology, oncology, cell biology, gene therapy, immunology, virology, diabetes, tissue procurement, transplantation, pharmacology, AIDS research, microbiology, infectious disease, neurobiology, tissue modeling and cell banking.

Projects are customized to the needs of the individual client with up-front discussions of scope of work, deliverables and costs. Some examples of current projects are: testing of anti-cancer agents for organ specificity and concentration efficacy in vitro and in animal models; evaluation of anti-viral drugs for effective dose; biological and gene therapies against the Kaposi's sarcoma-associated herpesvirus; testing of new agents against the human immunodeficiency virus, HIV; compound toxicity comparing normal versus diseased cells; gastrointestinal cell physiology and toxicology; angiogenesis and (cardio)vascular factor assays; multi-organ site and embryo fibroblast cultures from transgenic and non-transgenic animals; marker selection of genetically engineered human and animal cells; continuous cell line development and characterization; propagation of progenitor stem cells from cadaver donor tissues; banking and expansion of human neural, blood, and other organ site stem cells for research or clinical use; formulation and production of new specialty cell culture media and supplements; molecular and immunological assays of cell regulation (e.g., apoptosis or membrane transport), antigen expression; and cell co-cultivation and tissue modeling.

INCELL's clinical applications are focused on cell-based therapeutics that utilize cells from donors without disease, as well as diseased donors seeking customized therapy. Examples of the latter are patients with cancer or those with infectious agents such as HIV. Other treatments are targeted against genetic deficiencies, neural dysfunction (such as spinal cord injury or Parkinson's disease), and tissue/organ malfunction (e.g., diabetes, liver, or cardiovascular disease). Research development activities are supported by contracts and grants.